Saddle River, New Jersey, United States In 1986 was created Sigma Group, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Saddle River. The company was established in North America in United States.
Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Germany. Among the most popular portfolio startups of the fund, we may highlight CureVac.
The standard case for the fund is to invest in rounds with 7 partakers. Despite the Sigma Group, startups are often financed by dievini Hopp Biotech Holding, Bill & Melinda Gates Foundation. The meaningful sponsors for the fund in investment in the same round are dievini Hopp Biotech Holding, Northview LifeSciences, Coppel Family. In the next rounds fund is usually obtained by Landeskreditbank Baden-Wu00fcrttemberg, LBBW Asset Management, Baden-Wu00fcrttembergische Versorgungsanstalt fu00fcr u00c4rzte.
The typical startup value when the investment from Sigma Group is more than 1 billion dollars. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2015.
Related Funds
| Fund Name | Location |
| 54 Capital | Mayfair, United Kingdom, Westminster |
| Bayside Capital | Boston, Massachusetts, United States |
| BCN Ventures | Barcelona, Catalonia, Spain |
| Empower Group | Jericho, New York, United States |
| KD Capital L.L.C | Arizona, Scottsdale, United States |
| QED Investors | Alexandria, United States, Virginia |
| Sanzheng Health | - |
| Shunze Investment | - |
| West Security Innovation Invesetment | China, Chongqing, Jiangbei |
| Yellow Brick Capital Advisers | England, London, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ten63 Therapeutics | $15M | 02 May 2023 | Durham, North Carolina, United States | ||
Exogene | $2M | 25 Apr 2022 | London, England, United Kingdom |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ten63 Therapeutics | $15M | 02 May 2023 | Durham, North Carolina, United States | ||
Exogene | $2M | 25 Apr 2022 | London, England, United Kingdom |
